Personalis Key Executives
This section highlights Personalis's key executives, including their titles and compensation details.
Find Contacts at Personalis
(Showing 0 of )
Personalis Earnings
This section highlights Personalis's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $-0.32 | $-0.23 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-0.33 | $-0.64 |
| Read Transcript | Q2 | 2024 | 2024-08-07 | $-0.34 | $-0.24 |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $-0.44 | $-0.26 |
| Read Transcript | Q4 | 2023 | 2024-02-28 | $-0.53 | $-0.46 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $-0.54 | $-0.51 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $-0.56 | $-0.50 |
| Read Transcript | Q1 | 2023 | 2023-05-03 | $-0.62 | $-0.61 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
$3.75
Stock Price
$331.16M
Market Cap
229
Employees
Menlo Park, CA
Location
Financial Statements
Access annual & quarterly financial statements for Personalis, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $84.61M | $73.48M | $65.05M | $85.49M | $78.65M |
| Cost of Revenue | $57.79M | $55.27M | $51.70M | $53.84M | $58.53M |
| Gross Profit | $26.82M | $18.21M | $13.35M | $31.66M | $20.11M |
| Gross Profit Ratio | 31.70% | 24.78% | 20.52% | 37.03% | 25.57% |
| Research and Development Expenses | $48.91M | $64.78M | $64.91M | $49.31M | $28.57M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $46.19M | $49.73M | $63.97M | $47.70M | $33.69M |
| Other Expenses | $- | $13.64M | $61.00K | $-42.00K | $-24.00K |
| Operating Expenses | $95.09M | $128.14M | $128.88M | $97.01M | $62.26M |
| Cost and Expenses | $152.88M | $183.42M | $180.58M | $150.85M | $120.79M |
| Interest Income | $5.51M | $5.90M | $2.40M | $367.00K | $949.00K |
| Interest Expense | $24.00K | $110.00K | $201.00K | $184.00K | $2.00K |
| Depreciation and Amortization | $10.94M | $11.30M | $12.88M | $8.96M | $7.17M |
| EBITDA | $-70.30M | $-96.81M | $-104.64M | $-59.01M | $-34.05M |
| EBITDA Ratio | -83.08% | -131.74% | -160.87% | -69.03% | -43.30% |
| Operating Income | $-68.27M | $-109.94M | $-115.53M | $-65.35M | $-42.15M |
| Operating Income Ratio | -80.68% | -149.61% | -177.61% | -76.44% | -53.59% |
| Total Other Income Expenses Net | $-13.00M | $1.72M | $2.26M | $141.00K | $923.00K |
| Income Before Tax | $-81.27M | $-108.21M | $-113.28M | $-65.21M | $-41.22M |
| Income Before Tax Ratio | -96.04% | -147.27% | -174.14% | -76.28% | -52.41% |
| Income Tax Expense | $18.00K | $83.00K | $40.00K | $14.00K | $57.00K |
| Net Income | $-81.28M | $-108.30M | $-113.31M | $-65.23M | $-41.28M |
| Net Income Ratio | -96.06% | -147.38% | -174.20% | -76.29% | -52.49% |
| EPS | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.06 |
| EPS Diluted | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.06 |
| Weighted Average Shares Outstanding | 59.25M | 48.18M | 45.70M | 43.89M | 39.11M |
| Weighted Average Shares Outstanding Diluted | 59.25M | 48.18M | 45.70M | 43.89M | 39.11M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.80M | $25.71M | $22.58M | $19.52M | $19.68M | $18.25M | $16.70M | $18.86M | $16.72M | $14.86M | $18.24M | $15.23M | $20.68M | $22.26M | $21.67M | $20.88M | $20.18M | $19.82M | $19.50M | $19.16M |
| Cost of Revenue | $12.25M | $16.96M | $14.54M | $14.03M | $14.47M | $14.77M | $11.91M | $14.13M | $14.41M | $12.38M | $13.96M | $10.95M | $12.69M | $14.20M | $13.50M | $13.45M | $14.11M | $14.48M | $14.82M | $15.12M |
| Gross Profit | $4.55M | $8.74M | $8.04M | $5.49M | $5.21M | $3.48M | $4.79M | $4.73M | $2.31M | $2.48M | $4.28M | $4.28M | $8.00M | $8.07M | $8.17M | $7.43M | $6.07M | $5.33M | $4.67M | $4.04M |
| Gross Profit Ratio | 27.08% | 34.02% | 35.59% | 28.13% | 26.45% | 19.08% | 28.70% | 25.08% | 13.83% | 16.68% | 23.47% | 28.09% | 38.66% | 36.23% | 37.69% | 35.57% | 30.09% | 26.91% | 23.97% | 21.08% |
| Research and Development Expenses | $11.49M | $11.68M | $12.96M | $12.77M | $13.61M | $16.74M | $17.85M | $16.57M | $16.57M | $14.96M | $16.29M | $17.10M | $14.51M | $13.62M | $11.69M | $9.50M | $8.52M | $7.19M | $6.46M | $6.39M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $11.17M | $11.44M | $11.97M | $11.60M | $11.52M | $11.97M | $12.13M | $14.10M | $17.83M | $14.78M | $15.87M | $15.49M | $13.71M | $12.14M | $11.43M | $10.42M | $10.92M | $7.79M | $7.71M | $7.27M |
| Other Expenses | $- | $- | $2.97M | $4.57M | $-4.08M | $32.00K | $1.00K | $-26.00K | $-88.00K | $80.00K | $50.00K | $19.00K | $1.00K | $5.00K | $-36.00K | $-12.00K | $-29.00K | $-4.00K | $1.00K | $8.00K |
| Operating Expenses | $22.66M | $23.13M | $24.93M | $24.37M | $25.14M | $28.71M | $29.99M | $30.67M | $34.40M | $29.74M | $32.16M | $32.58M | $28.22M | $25.76M | $23.11M | $19.92M | $19.44M | $14.99M | $14.17M | $13.66M |
| Cost and Expenses | $34.91M | $40.09M | $39.47M | $38.41M | $39.61M | $43.48M | $41.89M | $44.80M | $48.81M | $42.12M | $46.12M | $43.53M | $40.91M | $39.95M | $36.62M | $33.37M | $33.55M | $29.47M | $28.99M | $28.79M |
| Interest Income | $1.63M | $1.38M | $1.14M | $1.36M | $1.48M | $1.71M | $1.47M | $1.25M | $1.16M | $743.00K | $349.00K | $144.00K | $81.00K | $88.00K | $103.00K | $95.00K | $76.00K | $117.00K | $246.00K | $510.00K |
| Interest Expense | $1.00K | $7.00K | $9.00K | $9.00K | $9.00K | $15.00K | $39.00K | $47.00K | $47.00K | $45.00K | $50.00K | $59.00K | $59.00K | $60.00K | $65.00K | $95.00K | $76.00K | $117.00K | $246.00K | $2.00K |
| Depreciation and Amortization | $2.54M | $2.76M | $2.80M | $2.84M | $2.91M | $2.76M | $3.43M | $3.32M | $3.79M | $3.05M | $2.17M | $3.87M | $2.82M | $2.38M | $1.87M | $1.90M | $1.48M | $1.46M | $1.42M | $1.40M |
| EBITDA | $-13.88M | $-36.32M | $-9.99M | $-10.12M | $-23.66M | $-26.30M | $-20.45M | $-25.28M | $-27.22M | $-23.39M | $-25.32M | $-26.37M | $-18.54M | $-16.09M | $-13.49M | $-10.88M | $-11.89M | $-8.19M | $-8.08M | $-7.71M |
| EBITDA Ratio | -82.61% | -141.28% | -44.22% | -51.81% | -120.27% | -144.11% | -122.46% | -134.03% | -162.80% | -157.39% | -138.79% | -173.17% | -89.65% | -72.30% | -62.27% | -52.12% | -58.94% | -41.33% | -41.44% | -40.24% |
| Operating Income | $-18.11M | $-14.38M | $-16.89M | $-18.88M | $-19.93M | $-30.79M | $-25.35M | $-25.94M | $-32.09M | $-27.26M | $-27.88M | $-28.31M | $-20.23M | $-17.69M | $-14.95M | $-12.49M | $-13.37M | $-9.65M | $-9.50M | $-9.62M |
| Operating Income Ratio | -107.81% | -55.94% | -74.81% | -96.70% | -101.31% | -168.76% | -151.78% | -137.54% | -191.87% | -183.46% | -152.86% | -185.89% | -97.79% | -79.47% | -68.98% | -59.82% | -66.27% | -48.71% | -48.72% | -50.23% |
| Total Other Income Expenses Net | $1.69M | $-24.70M | $4.09M | $5.92M | $-2.61M | $1.72M | $1.43M | $1.18M | $1.02M | $778.00K | $349.00K | $104.00K | $23.00K | $33.00K | $2.00K | $83.00K | $47.00K | $113.00K | $247.00K | $516.00K |
| Income Before Tax | $-16.42M | $-39.09M | $-12.80M | $-12.96M | $-26.58M | $-29.07M | $-23.92M | $-28.64M | $-31.06M | $-26.48M | $-27.53M | $-28.20M | $-20.20M | $-17.66M | $-14.95M | $-12.41M | $-13.32M | $-9.54M | $-9.25M | $-9.11M |
| Income Before Tax Ratio | -97.74% | -152.03% | -56.68% | -66.38% | -135.09% | -159.31% | -143.24% | -151.88% | -185.74% | -178.23% | -150.94% | -185.21% | -97.68% | -79.32% | -68.97% | -59.42% | -66.03% | -48.14% | -47.45% | -47.54% |
| Income Tax Expense | $4.00K | $3.00K | $4.00K | $7.00K | $5.00K | $28.00K | $36.00K | $14.00K | $8.00K | $11.00K | $14.00K | $7.00K | $-3.00K | $12.00K | $8.00K | $-3.00K | $18.00K | $5.00K | $4.00K | $30.00K |
| Net Income | $-16.43M | $-39.09M | $-12.80M | $-12.97M | $-26.58M | $-29.10M | $-23.95M | $-28.66M | $-31.07M | $-26.49M | $-27.55M | $-28.21M | $-20.20M | $-17.67M | $-14.95M | $-12.40M | $-13.34M | $-9.54M | $-9.26M | $-9.14M |
| Net Income Ratio | -97.77% | -152.04% | -56.70% | -66.42% | -135.12% | -159.47% | -143.45% | -151.96% | -185.79% | -178.30% | -151.02% | -185.26% | -97.66% | -79.38% | -69.00% | -59.40% | -66.12% | -48.17% | -47.47% | -47.70% |
| EPS | $-0.23 | $-0.64 | $-0.24 | $-0.26 | $-0.54 | $-0.60 | $-0.50 | $-0.61 | $-0.67 | $-0.58 | $-0.60 | $-0.63 | $-0.45 | $-0.40 | $-0.34 | $-0.29 | $-0.38 | $-0.27 | $-0.29 | $-0.29 |
| EPS Diluted | $-0.23 | $-0.64 | $-0.24 | $-0.26 | $-0.54 | $-0.60 | $-0.50 | $-0.61 | $-0.67 | $-0.58 | $-0.60 | $-0.63 | $-0.45 | $-0.40 | $-0.34 | $-0.29 | $-0.38 | $-0.27 | $-0.29 | $-0.29 |
| Weighted Average Shares Outstanding | 72.88M | 61.05M | 52.39M | 50.68M | 49.60M | 48.69M | 47.67M | 46.74M | 46.26M | 45.92M | 45.64M | 45.00M | 44.45M | 44.51M | 43.96M | 42.27M | 35.46M | 35.46M | 31.73M | 31.35M |
| Weighted Average Shares Outstanding Diluted | 72.88M | 61.05M | 52.39M | 50.68M | 49.60M | 48.69M | 47.67M | 46.74M | 46.26M | 45.92M | 45.64M | 45.00M | 44.81M | 44.51M | 43.96M | 42.27M | 35.46M | 35.46M | 31.73M | 31.35M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $91.42M | $56.98M | $89.13M | $105.58M | $68.53M |
| Short Term Investments | $93.59M | $57.20M | $78.53M | $181.48M | $134.76M |
| Cash and Short Term Investments | $185.01M | $114.18M | $167.66M | $287.06M | $203.29M |
| Net Receivables | $8.14M | $17.73M | $16.64M | $18.47M | $6.35M |
| Inventory | $3.98M | $5.66M | $8.59M | $5.61M | $2.67M |
| Other Current Assets | $5.89M | $9.17M | $9.02M | $14.18M | $10.88M |
| Total Current Assets | $203.01M | $146.74M | $199.70M | $318.23M | $220.72M |
| Property Plant Equipment Net | $64.73M | $75.22M | $88.42M | $73.47M | $22.11M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $1.79M | $1.79M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.53M | $1.35M | $2.80M | $4.83M | $2.02M |
| Total Non-Current Assets | $67.25M | $78.36M | $93.00M | $78.30M | $24.12M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $270.27M | $225.10M | $292.70M | $396.53M | $244.84M |
| Account Payables | $6.40M | $14.92M | $12.85M | $9.22M | $8.30M |
| Short Term Debt | $9.37M | $9.41M | $7.61M | $5.53M | $2.44M |
| Tax Payables | $- | $37.00K | $123.00K | $121.00K | $95.00K |
| Deferred Revenue | $3.10M | $3.29M | $1.26M | $3.98M | $21.03M |
| Other Current Liabilities | $12.26M | $19.58M | $12.54M | $16.44M | $8.76M |
| Total Current Liabilities | $31.13M | $47.23M | $33.13M | $31.31M | $40.64M |
| Long Term Debt | $34.88M | $39.55M | $41.04M | $52.80M | $8.54M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.30M | $8.87M | $389.00K | $2.12M | $720.00K |
| Total Non-Current Liabilities | $36.19M | $48.42M | $41.43M | $54.91M | $9.26M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $67.31M | $95.66M | $74.56M | $86.23M | $49.90M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $5.00K | $5.00K | $4.00K | $4.00K |
| Retained Earnings | $-549.99M | $-468.71M | $-360.41M | $-247.09M | $-181.87M |
| Accumulated Other Comprehensive Income Loss | $-23.00K | $-222.00K | $-912.00K | $-166.00K | $22.00K |
| Other Total Stockholders Equity | $752.96M | $598.36M | $579.46M | $557.56M | $376.79M |
| Total Stockholders Equity | $202.96M | $129.44M | $218.14M | $310.30M | $194.94M |
| Total Equity | $202.96M | $129.44M | $218.14M | $310.30M | $194.94M |
| Total Liabilities and Stockholders Equity | $270.27M | $225.10M | $292.70M | $396.53M | $244.84M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $270.27M | $225.10M | $292.70M | $396.53M | $244.84M |
| Total Investments | $93.59M | $58.98M | $78.53M | $181.48M | $134.76M |
| Total Debt | $44.25M | $48.96M | $48.65M | $52.80M | $10.99M |
| Net Debt | $-47.17M | $-8.02M | $-40.48M | $-52.79M | $-57.54M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $91.42M | $75.80M | $47.75M | $43.98M | $56.98M | $72.19M | $97.19M | $87.17M | $89.13M | $83.52M | $86.73M | $91.59M | $105.58M | $79.57M | $70.08M | $137.09M | $68.53M | $133.25M | $25.04M | $46.69M |
| Short Term Investments | $93.59M | $67.85M | $39.23M | $51.44M | $57.20M | $48.47M | $40.01M | $61.77M | $78.53M | $109.23M | $146.76M | $174.95M | $181.48M | $225.66M | $258.83M | $216.34M | $134.76M | $72.82M | $80.19M | $73.34M |
| Cash and Short Term Investments | $185.01M | $143.65M | $86.97M | $95.42M | $114.18M | $120.66M | $137.21M | $148.94M | $167.66M | $192.76M | $233.49M | $266.54M | $287.06M | $305.23M | $328.91M | $353.43M | $203.29M | $206.06M | $105.23M | $120.03M |
| Net Receivables | $8.14M | $13.47M | $12.92M | $11.35M | $17.73M | $13.67M | $10.13M | $18.10M | $16.64M | $13.59M | $12.88M | $13.52M | $18.47M | $10.53M | $9.28M | $8.05M | $6.35M | $5.90M | $5.38M | $5.51M |
| Inventory | $3.98M | $8.49M | $4.69M | $4.97M | $5.66M | $8.22M | $4.77M | $5.52M | $8.59M | $5.86M | $6.51M | $4.82M | $5.61M | $3.82M | $7.32M | $2.03M | $2.67M | $2.63M | $3.25M | $3.92M |
| Other Current Assets | $5.89M | $4.66M | $8.09M | $9.82M | $8.72M | $11.32M | $10.95M | $10.21M | $9.02M | $9.70M | $7.17M | $9.15M | $14.18M | $15.46M | $17.61M | $11.21M | $10.88M | $10.72M | $5.98M | $5.96M |
| Total Current Assets | $203.01M | $170.28M | $108.63M | $116.65M | $141.93M | $148.22M | $160.96M | $182.77M | $199.70M | $221.91M | $260.04M | $294.03M | $318.23M | $329.01M | $354.31M | $372.67M | $220.72M | $223.59M | $120.12M | $135.42M |
| Property Plant Equipment Net | $64.73M | $67.05M | $69.83M | $72.04M | $75.22M | $74.92M | $84.15M | $85.42M | $88.42M | $91.26M | $93.50M | $82.33M | $73.47M | $72.61M | $25.38M | $21.05M | $22.11M | $23.37M | $23.64M | $14.93M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.53M | $2.56M | $5.25M | $4.79M | $6.16M | $1.71M | $2.15M | $2.20M | $2.80M | $2.90M | $4.44M | $4.29M | $4.83M | $5.07M | $3.65M | $1.79M | $2.02M | $1.85M | $1.76M | $1.53M |
| Total Non-Current Assets | $67.25M | $69.61M | $76.87M | $78.63M | $83.17M | $78.42M | $88.08M | $89.41M | $93.00M | $95.95M | $97.94M | $86.62M | $78.30M | $77.68M | $29.03M | $22.84M | $24.12M | $25.22M | $25.40M | $16.46M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $270.27M | $239.89M | $185.50M | $195.28M | $225.10M | $226.64M | $249.04M | $272.18M | $292.70M | $317.86M | $357.98M | $380.65M | $396.53M | $406.69M | $383.34M | $395.51M | $244.84M | $248.81M | $145.52M | $151.88M |
| Account Payables | $6.40M | $12.45M | $9.94M | $9.18M | $14.92M | $8.96M | $8.85M | $10.93M | $12.85M | $10.78M | $21.39M | $12.28M | $9.22M | $7.29M | $8.92M | $6.52M | $8.30M | $6.51M | $7.49M | $10.34M |
| Short Term Debt | $9.37M | $7.91M | $9.42M | $9.46M | $9.41M | $8.12M | $8.07M | $8.79M | $7.61M | $7.11M | $6.38M | $5.97M | $5.53M | $5.33M | $6.15M | $2.47M | $2.44M | $2.30M | $2.11M | $1.11M |
| Tax Payables | $- | $7.00K | $38.00K | $50.00K | $37.00K | $93.00K | $100.00K | $134.00K | $123.00K | $526.00K | $506.00K | $535.00K | $121.00K | $478.00K | $446.00K | $101.00K | $95.00K | $46.00K | $37.00K | $57.00K |
| Deferred Revenue | $3.10M | $- | $4.17M | $3.53M | $3.29M | $3.69M | $3.36M | $2.59M | $1.26M | $327.00K | $386.00K | $3.49M | $3.98M | $2.97M | $11.46M | $18.24M | $21.03M | $20.59M | $28.95M | $34.41M |
| Other Current Liabilities | $12.26M | $16.05M | $14.74M | $12.68M | $22.87M | $15.31M | $11.57M | $14.30M | $12.54M | $15.32M | $13.22M | $21.06M | $16.44M | $10.46M | $7.12M | $11.23M | $8.76M | $6.45M | $4.45M | $6.21M |
| Total Current Liabilities | $31.13M | $36.41M | $34.13M | $31.37M | $47.23M | $32.48M | $28.59M | $34.14M | $33.13M | $33.74M | $41.51M | $39.84M | $31.31M | $26.52M | $34.09M | $38.56M | $40.64M | $35.90M | $43.04M | $52.12M |
| Long Term Debt | $34.88M | $36.01M | $37.24M | $38.36M | $39.55M | $39.17M | $40.72M | $40.70M | $41.04M | $41.72M | $51.84M | $54.08M | $52.80M | $54.53M | $10.15M | $8.16M | $8.54M | $8.90M | $9.23M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.30M | $701.00K | $1.85M | $4.85M | $8.87M | $3.79M | $3.64M | $3.71M | $389.00K | $4.00K | $5.00K | $8.00K | $2.12M | $356.00K | $356.00K | $360.00K | $720.00K | $471.00K | $129.00K | $- |
| Total Non-Current Liabilities | $36.19M | $36.71M | $39.10M | $43.21M | $48.42M | $42.95M | $44.36M | $44.41M | $41.43M | $41.72M | $51.84M | $54.09M | $54.91M | $54.88M | $10.51M | $8.52M | $9.26M | $9.37M | $9.36M | $556.00K |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $67.31M | $73.13M | $73.23M | $74.58M | $95.66M | $75.43M | $72.95M | $78.55M | $74.56M | $75.46M | $93.35M | $93.93M | $86.23M | $81.40M | $44.59M | $47.09M | $49.90M | $45.27M | $52.40M | $52.68M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $7.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K |
| Retained Earnings | $-549.99M | $-533.57M | $-494.48M | $-481.67M | $-468.71M | $-442.12M | $-413.02M | $-389.07M | $-360.41M | $-329.34M | $-302.85M | $-275.30M | $-247.09M | $-226.90M | $-209.23M | $-194.27M | $-181.87M | $-168.53M | $-158.98M | $-149.73M |
| Accumulated Other Comprehensive Income Loss | $-23.00K | $87.00K | $-120.00K | $-125.00K | $-222.00K | $-302.00K | $-313.00K | $-455.00K | $-912.00K | $-1.42M | $-1.26M | $-875.00K | $-166.00K | $12.00K | $18.00K | $-5.00K | $22.00K | $37.00K | $106.00K | $73.00K |
| Other Total Stockholders Equity | $752.96M | $700.23M | $606.86M | $602.49M | $598.36M | $593.62M | $589.42M | $583.15M | $579.46M | $573.16M | $568.74M | $562.89M | $557.56M | $552.18M | $547.95M | $542.69M | $376.79M | $372.03M | $252.00M | $248.85M |
| Total Stockholders Equity | $202.96M | $166.76M | $112.27M | $120.69M | $129.44M | $151.21M | $176.09M | $193.63M | $218.14M | $242.40M | $264.63M | $286.71M | $310.30M | $325.30M | $338.75M | $348.42M | $194.94M | $203.54M | $93.12M | $99.20M |
| Total Equity | $202.96M | $166.76M | $112.27M | $120.69M | $129.44M | $151.21M | $176.09M | $193.63M | $218.14M | $242.40M | $264.63M | $286.71M | $310.30M | $325.30M | $338.75M | $348.42M | $194.94M | $203.54M | $93.12M | $99.20M |
| Total Liabilities and Stockholders Equity | $270.27M | $239.89M | $185.50M | $195.28M | $225.10M | $226.64M | $249.04M | $272.18M | $292.70M | $317.86M | $357.98M | $380.65M | $396.53M | $406.69M | $383.34M | $395.51M | $244.84M | $248.81M | $145.52M | $151.88M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $270.27M | $239.89M | $185.50M | $195.28M | $225.10M | $226.64M | $249.04M | $272.18M | $292.70M | $317.86M | $357.98M | $380.65M | $396.53M | $406.69M | $383.34M | $395.51M | $244.84M | $248.81M | $145.52M | $151.88M |
| Total Investments | $93.59M | $67.85M | $41.02M | $53.23M | $58.98M | $48.47M | $40.01M | $61.77M | $78.53M | $109.23M | $146.76M | $174.95M | $181.48M | $225.66M | $258.83M | $216.34M | $134.76M | $72.82M | $80.19M | $73.34M |
| Total Debt | $44.25M | $45.16M | $46.66M | $47.82M | $48.96M | $39.17M | $48.79M | $49.48M | $48.65M | $48.83M | $58.22M | $60.05M | $52.80M | $59.85M | $8.52M | $10.63M | $10.99M | $11.20M | $11.34M | $1.11M |
| Net Debt | $-47.17M | $-30.64M | $-1.08M | $3.84M | $-8.02M | $-33.03M | $-48.40M | $-37.69M | $-40.48M | $-34.69M | $-28.51M | $-31.53M | $-52.79M | $-19.72M | $-61.56M | $-126.46M | $-57.54M | $-122.05M | $-13.70M | $-45.59M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-81.28M | $-108.30M | $-113.31M | $-65.23M | $-41.28M |
| Depreciation and Amortization | $10.94M | $11.30M | $8.43M | $6.01M | $5.76M |
| Deferred Income Tax | $- | $- | $- | $2.03M | $391.00K |
| Stock Based Compensation | $10.69M | $14.05M | $19.43M | $14.38M | $8.24M |
| Change in Working Capital | $-2.59M | $13.48M | $10.61M | $-31.14M | $-17.23M |
| Accounts Receivables | $9.59M | $-1.09M | $1.82M | $-12.12M | $-3.05M |
| Inventory | $4.42M | $-1.93M | $-2.98M | $29.00K | $-1.08M |
| Accounts Payables | $-8.92M | $5.18M | $3.09M | $-1.46M | $751.00K |
| Other Working Capital | $-7.68M | $11.33M | $8.68M | $-17.60M | $-13.86M |
| Other Non Cash Items | $17.10M | $13.21M | $4.61M | $3.12M | $1.47M |
| Net Cash Provided by Operating Activities | $-45.15M | $-56.26M | $-70.23M | $-70.83M | $-42.65M |
| Investments in Property Plant and Equipment | $-1.60M | $-10.91M | $-49.90M | $-11.08M | $-3.25M |
| Acquisitions Net | $- | $-24.01M | $-102.43M | $48.99M | $65.14M |
| Purchases of Investments | $-121.71M | $-103.94M | $-121.49M | $-267.13M | $-161.78M |
| Sales Maturities of Investments | $88.00M | $127.95M | $223.92M | $218.14M | $99.88M |
| Other Investing Activities | $242.00K | $24.01M | $102.43M | $-48.99M | $-65.14M |
| Net Cash Used for Investing Activities | $-35.07M | $13.10M | $52.54M | $-60.07M | $-65.14M |
| Debt Repayment | $-1.13M | $174.00K | $-1.10M | $3.31M | $- |
| Common Stock Issued | $97.82M | $3.51M | $2.46M | $162.26M | $117.50M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $17.98M | $7.34M | $2.46M | $4.13M | $3.77M |
| Net Cash Used Provided by Financing Activities | $114.67M | $11.03M | $1.37M | $169.70M | $121.27M |
| Effect of Forex Changes on Cash | $-22.00K | $-16.00K | $-127.00K | $47.00K | $7.00K |
| Net Change in Cash | $34.43M | $-32.14M | $-16.46M | $38.85M | $13.48M |
| Cash at End of Period | $93.20M | $56.98M | $90.92M | $107.38M | $68.53M |
| Cash at Beginning of Period | $58.77M | $89.13M | $107.38M | $68.53M | $55.05M |
| Operating Cash Flow | $-45.15M | $-56.26M | $-70.23M | $-70.83M | $-42.65M |
| Capital Expenditure | $-1.60M | $-10.91M | $-49.90M | $-11.08M | $-3.25M |
| Free Cash Flow | $-46.75M | $-67.17M | $-120.13M | $-81.91M | $-45.90M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-16.43M | $-39.09M | $-12.80M | $-12.97M | $-26.58M | $-29.10M | $-23.95M | $-28.66M | $-31.07M | $-26.49M | $-27.55M | $-28.21M | $-20.20M | $-17.67M | $-14.95M | $-12.40M | $-13.34M | $-9.54M | $-9.26M | $-9.14M |
| Depreciation and Amortization | $2.54M | $932.00K | $2.80M | $2.84M | $2.91M | $2.76M | $2.85M | $2.78M | $2.96M | $1.88M | $1.82M | $1.77M | $1.60M | $1.50M | $1.39M | $1.52M | $1.48M | $1.46M | $1.42M | $1.40M |
| Deferred Income Tax | $- | $- | $- | $- | $-7.34M | $4.91M | $-350.00K | $- | $- | $- | $- | $- | $477.00K | $542.00K | $516.00K | $496.00K | $391.00K | $- | $- | $- |
| Stock Based Compensation | $2.67M | $2.68M | $2.65M | $2.69M | $3.39M | $3.48M | $3.48M | $3.69M | $5.79M | $4.42M | $4.42M | $4.82M | $4.03M | $3.69M | $3.60M | $3.06M | $3.48M | $1.69M | $1.82M | $1.25M |
| Change in Working Capital | $3.86M | $8.06M | $-40.00K | $-8.02M | $1.20M | $-270.00K | $7.61M | $4.94M | $4.91M | $4.42M | $-6.50M | $7.78M | $-2.46M | $-6.86M | $-17.03M | $-4.79M | $5.10M | $-10.20M | $-9.73M | $-2.40M |
| Accounts Receivables | $5.33M | $-554.00K | $-1.58M | $6.38M | $-4.06M | $-3.53M | $7.97M | $-1.46M | $-3.05M | $-715.00K | $642.00K | $4.95M | $-7.93M | $-1.26M | $-1.23M | $-1.70M | $-446.00K | $-528.00K | $133.00K | $-2.21M |
| Inventory | $2.45M | $708.00K | $-436.00K | $1.71M | $-2.13M | $-94.00K | $33.00K | $262.00K | $-1.05M | $341.00K | $179.00K | $-2.46M | $-88.00K | $1.80M | $-1.74M | $61.00K | $586.00K | $256.00K | $-86.00K | $-1.83M |
| Accounts Payables | $-4.79M | $966.00K | $536.00K | $-5.64M | $5.93M | $604.00K | $54.00K | $-1.41M | $4.16M | $-1.15M | $-1.05M | $1.13M | $2.07M | $-3.46M | $2.10M | $-2.17M | $2.38M | $-1.28M | $-2.73M | $2.38M |
| Other Working Capital | $866.00K | $6.94M | $1.00M | $-8.77M | $1.47M | $2.75M | $-443.00K | $7.55M | $4.85M | $5.95M | $-3.10M | $4.15M | $3.49M | $-3.95M | $-16.16M | $-977.00K | $2.58M | $-8.65M | $-7.05M | $-745.00K |
| Other Non Cash Items | $-441.00K | $21.23M | $5.94M | $2.66M | $13.01M | $1.54M | $-57.00K | $1.50M | $652.00K | $1.01M | $323.00K | $2.49M | $1.28M | $916.00K | $548.00K | $379.00K | $358.00K | $465.00K | $395.00K | $251.00K |
| Net Cash Provided by Operating Activities | $-7.80M | $-6.20M | $-10.74M | $-20.41M | $-13.42M | $-16.68M | $-10.41M | $-15.74M | $-16.76M | $-14.77M | $-27.35M | $-11.36M | $-15.27M | $-17.88M | $-25.93M | $-11.74M | $-2.53M | $-16.12M | $-15.35M | $-8.64M |
| Investments in Property Plant and Equipment | $-1.25M | $-247.00K | $-6.00K | $-104.00K | $-3.52M | $-868.00K | $-2.74M | $-3.78M | $-9.54M | $-21.41M | $-10.31M | $-8.63M | $-3.58M | $-2.96M | $-4.11M | $-439.00K | $-837.00K | $-1.55M | $-779.00K | $-76.00K |
| Acquisitions Net | $- | $- | $240.00K | $- | $- | $7.74M | $-22.29M | $-17.57M | $-31.39M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-44.94M | $-38.93M | $-8.74M | $-29.09M | $-32.11M | $-47.94M | $-2.37M | $-21.53M | $-10.31M | $-21.12M | $-30.36M | $-59.70M | $-39.81M | $-20.64M | $-92.62M | $-114.06M | $-81.67M | $-13.00M | $-39.87M | $-27.24M |
| Sales Maturities of Investments | $20.00M | $28.75M | $21.50M | $35.50M | $24.00M | $40.20M | $24.66M | $39.10M | $41.70M | $58.82M | $58.23M | $65.17M | $83.30M | $53.27M | $49.62M | $31.95M | $19.37M | $20.20M | $33.03M | $27.28M |
| Other Investing Activities | $2.00K | $-17.75M | $240.00K | $6.41M | $-1 | $-7.74M | $22.29M | $17.57M | $31.39M | $-5.46M | $33.33M | $5.47M | $43.49M | $32.63M | $-43.00M | $-82.11M | $-62.30M | $7.20M | $-6.84M | $41.00K |
| Net Cash Used for Investing Activities | $-26.18M | $-28.18M | $12.99M | $6.30M | $-11.64M | $-8.61M | $19.55M | $13.79M | $21.85M | $10.83M | $23.02M | $-3.16M | $39.91M | $29.67M | $-47.10M | $-82.54M | $-63.14M | $5.65M | $-7.62M | $-35.00K |
| Debt Repayment | $-308.00K | $-308.00K | $-206.00K | $-308.00K | $2.47M | $-435.00K | $- | $- | $- | $758.00K | $- | $- | $- | $-1.04M | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $50.00M | $44.98M | $1.41M | $1.44M | $915.00K | $725.00K | $1.87M | $- | $511.00K | $2.00K | $1.44M | $515.00K | $1.35M | $536.00K | $1.66M | $162.26M | $-117.50M | $117.50M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-91.00K | $17.75M | $317.00K | $- | $7.35M | $- | $925.00K | $- | $511.00K | $2.00K | $-420.00K | $515.00K | $1.35M | $536.00K | $6.01M | $591.00K | $941.00K | $1.18M | $1.32M | $323.00K |
| Net Cash Used Provided by Financing Activities | $49.60M | $62.43M | $1.52M | $1.13M | $9.82M | $290.00K | $925.00K | $- | $511.00K | $760.00K | $-420.00K | $515.00K | $1.35M | $-506.00K | $6.01M | $162.85M | $941.00K | $118.68M | $1.32M | $323.00K |
| Effect of Forex Changes on Cash | $-7.00K | $5.00K | $- | $-20.00K | $32.00K | $-7.00K | $-37.00K | $-4.00K | $6.00K | $-30.00K | $-107.00K | $4.00K | $29.00K | $-1.00K | $17.00K | $2.00K | $11.00K | $-3.00K | $-4.00K | $3.00K |
| Net Change in Cash | $15.62M | $29.84M | $3.77M | $-13.00M | $-15.21M | $-25.00M | $10.02M | $-1.96M | $5.61M | $-3.21M | $-4.86M | $-14.00M | $26.01M | $11.28M | $-67.01M | $68.56M | $-64.72M | $108.20M | $-21.65M | $-8.35M |
| Cash at End of Period | $93.20M | $77.59M | $47.75M | $43.98M | $56.98M | $73.98M | $98.98M | $88.96M | $90.92M | $85.31M | $88.52M | $93.38M | $107.38M | $81.36M | $70.08M | $137.09M | $68.53M | $133.25M | $25.04M | $46.69M |
| Cash at Beginning of Period | $77.59M | $47.75M | $43.98M | $56.98M | $72.19M | $98.98M | $88.96M | $90.92M | $85.31M | $88.52M | $93.38M | $107.38M | $81.36M | $70.08M | $137.09M | $68.53M | $133.25M | $25.04M | $46.69M | $55.05M |
| Operating Cash Flow | $-7.80M | $-6.20M | $-10.74M | $-20.41M | $-13.42M | $-16.68M | $-10.41M | $-15.74M | $-16.76M | $-14.77M | $-27.35M | $-11.36M | $-15.27M | $-17.88M | $-25.93M | $-11.74M | $-2.53M | $-16.12M | $-15.35M | $-8.64M |
| Capital Expenditure | $-1.25M | $-247.00K | $-6.00K | $-104.00K | $-3.52M | $-868.00K | $-2.74M | $-3.78M | $-9.54M | $-21.41M | $-10.31M | $-8.63M | $-3.58M | $-2.96M | $-4.11M | $-439.00K | $-837.00K | $-1.55M | $-779.00K | $-76.00K |
| Free Cash Flow | $-9.04M | $-6.45M | $-10.75M | $-20.52M | $-16.94M | $-17.55M | $-13.15M | $-19.52M | $-26.30M | $-36.18M | $-37.66M | $-19.99M | $-18.85M | $-20.84M | $-30.04M | $-12.18M | $-3.37M | $-17.68M | $-16.13M | $-8.72M |
Personalis Dividends
Explore Personalis's dividend history, including dividend yield, payout ratio, and historical payments.
Personalis News
Read the latest news about Personalis, including recent articles, headlines, and updates.
Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer (CRC). The study, led by Dr. Jonathan Loree's team at BC Cancer in Vancouver, Canada, utilized NeXT Personal to look for small traces of circulating tumor DNA (ctDNA) in bloo.
Personalis to Announce First Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or.
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois. “Our collaborators are excited to present new data, including.
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the.
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease (MRD) and recurrence detection using NeXT Personal®, an ult.
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Exciting Technology At Personalis, But Profitability Eludes Them
Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financials with a good cash position and no debt, but struggles with test reimbursement impacting gross margins. Partnerships with Tempus AI and Merck provide capital and credibility, but profitability is projected to be years away, possibly until 2029.
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect.
Personalis price target raised to $9 from $7 at Lake Street
Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. With cash to breakeven, a strong commercial partner, "robust" clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as "another transformative year" for Personalis, the analyst tells investors.
Personalis to Participate at Upcoming Investor Conferences
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Fireside Chat Time: 12:30 pm Eastern Time Location: The Lotte New York Palace in New York, NY TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade Date: Thursday, December 12, 202.
Personalis to Announce Third Quarter 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic call.
Personalis: Resetting My Strategy Following The Q2 Beat
PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call.
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding ca.
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, June 21, 2024 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Personalis had previously announced it would host the conference call on Wednesday, June 19, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time. Webcast and Conference Call Information Interested parties may access the call by dia.
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT Personal test had exceptional detection rates and performance for early-stage breast cancer and immunotherapy monitoring. The NeXT Personal test is the first of a new class of ultra-sensitive liquid biopsy tests designed to detect the earliest traces of cancer recurrence a.
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis' ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus' commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung can.
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois. “As the body of studies continue.
Antares Bolsters Private Wealth Team with Three New Senior Appointments
CHICAGO--(BUSINESS WIRE)--Antares Capital (“Antares”), a leading alternative asset manager with more than $69B in capital under management and administration, today announced three new senior hires to support the expansion of the firm's private wealth strategy. “The private wealth community is increasingly seeking alternative investments to diversify their portfolios, reduce volatility and improve performance, so we are thrilled to welcome these industry experts to meet this growing demand and.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PSNL.